In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment

Journal of Psychiatric Research

Volumn 43, Issue 11, 2009, Pages 997-1002

  Reaven, Gerald M ^a   Lieberman, Jeffrey A ^b   Sethuraman, Gopalan ^c   Kraemer, Helena ^a   Davis, John M ^d   Blasey, Christine ^a   Tsuang, Ming T ^e   Schatzberg, Alan F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dyslipidemia; Glucose intolerance; Olanzapine; Schizophrenia; Signal detection method; Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 67649386886     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2009.01.010     Document Type: Article

References (21)

1. Abbasi F., Brown B.W.B., Lamendola C., McLaughlin T., and Reaven G.M. Relationship between obesity, insulin resistance, and coronary heart disease risk. Journal of American College of Cardiology 40 (2002) 937-943
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
3. American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29(Suppl. 1):S43-8.
4. Baldessarini R.J., and Tarzi F.I. Drugs and the treatment of psychiatric disorders, antipsychotic and antimanic agents. In: Hardman J.P., Limbird L.E., and Gillman A.G. (Eds). Goodman and Gillman's the pharmacological basis of therapeutics. 11th ed. (2005), McGraw Hill, New York [chapter 18]
5. Breier A., Berg P.H., Thakore J.H., Naber D., Gattaz W.F., Cavazzoni P., et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. American Journal of Psychiatry 162 (2005) 1879-1887
6. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association 2001;285:2486-97.
7. Gardner D.M., Balderssaini R.J., and Waraich P. Modern antipsychotic agents: a critical review. Canadian Medical Association Journal 172 (2005) 1703-1711
8. Kinon B.J., Lipkovich I., Edwards S.B., Adams D.H., Ascher-Svanum H., and Siris S.G. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. Journal of Clinical Psychopharmacology 26 (2006) 157-162
9. Kraemer H.C., Stice E., Kazdin A., Offord D., and Kupfer D. How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. American Journal of Psychiatry 158 (2001) 848-856
10. Kraemer H.C., Wilson G.T., Fairburn C.G., and Agras W.S. Mediators and moderators of treatment effects in randomized clinical trials. Archives of General Psychiatry 59 (2002) 877-883
11. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353 (2005) 1209-1223
12. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Case D.E., Davis J.M., et al. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161 (2004) 1334-1349
13. McLaughlin T., Abbasi F., Lamendola C., et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106 (2002) 2908-2912
14. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the Evidence Report. Bethesda, MD: National Institutes of Health, United States Department of Health and Human Services; 1998.
15. Reaven G.M. Obesity, insulin resistance, and cardiovascular disease. Recent Progress in Hormone Research 59 (2004) 207-223
16. Reaven G.M. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinology and Metabolism Clinics of North America 34 (2005) 49-62
17. Reaven G.M. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
18. Reaven G.M. Identifying the overweight patient who will benefit the most by losing weight. Annals of Internal Medicine 138 (2003) 420-423
19. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT). New England Journal of Medicine 341 (2005) 410-418
20. Simpson G.M., Weiden P., Pigott T., Murray S., Siu C.O., and Romano S.J. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. American Journal of Psychiatry 162 (2005) 1535-1538
21. Yeni-Komshian H., Carantoni M., Abbasi F., and Reaven G.M. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic individuals. Diabetes Care 23 (2000) 171-175